Hosted on MSN
Study backs Alterity’s innovative tool in diagnosing and monitoring MSA disease progression
Quality peer-reviewed publication highlights use of Alterity’s MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it ...
Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
Furthermore, the study – led by investigators at Vanderbilt University Medical Center in collaboration with Alterity Therapeutics’ (ASX:ATH) – found QSM can distinguish MSA from Parkinson’s disease ...
STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Alterity bioMUSE study shows advanced MRI imaging detects iron changes in the brain linked to diagnosis and severity in patients with Multiple System Atrophy (MSA). Published in leading human brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results